On May 15, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported it will present preclinical data on the Company’s pipeline of novel therapeutics in three presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place June 22-24, 2020 (Press release, Mirati, MAY 15, 2020, View Source [SID1234558181]). The data to be presented will include preclinical findings on MRTX849, a novel and optimized KRAS G12C inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to develop an increasing understanding of the role of KRAS in the pathogenesis of cancers as well as the consequences of direct therapeutic inhibition of KRAS. We continue to aspire to apply these learnings toward rational drug development and to make a real and timely impact on patient lives," said James G. Christensen, Ph.D. Executive Vice President and Chief Scientific Officer, Mirati Therapeutics.

Late-Breaking Poster Presentation Details:
Title: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models
Poster Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Presentation Date: June 22, 2020 (available via AACR (Free AACR Whitepaper)’s online platform)
Presenter: Jill Hallin, Principal Scientist, Biology, Mirati Therapeutics
Poster Number: LB-098

Minisymposium Session Details:
Title: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRAS G12C-mutant models
Session Title: Emerging Mechanisms of Resistance to Targeted Therapies
Presentation Date: June 24, 2020 (available via AACR (Free AACR Whitepaper)’s online platform)
Presenter: Lars Engstrom, Principal Scientist, Biology, Mirati Therapeutics
Abstract Number: 5684

Poster Presentation Details:
Title: MRTX2219 is an imidazopyrimidine binder to EED that inhibits polycomb repressive complex 2 (PRC2) and demonstrates robust in vivo activity in EZH2 and SMARCB1-mutant, but not other SWI/SNF-mutant cancer models
Poster Session Title: Epigenetic Targets
Presentation Date: June 22, 2020 (available via AACR (Free AACR Whitepaper)’s online platform)
Presenter: David Briere, Principal Scientist, Biology, Mirati Therapeutics
Poster Number: 1769

About MRTX849

MRTX849 is an investigational, orally available small molecule that is designed to potently and selectively inhibit a form of KRAS which harbors a substitution mutation (G12C). KRAS G12C mutations are present in approximately 14% of non-small cell lung cancer adenocarcinoma patients, 4% of colorectal cancer patients, and subsets of other types of cancer. Tumors characterized by KRAS G12C mutations are commonly associated with poor prognosis and resistance to therapy, and patients with these mutations have few treatment options. MRTX849 is being evaluated in a Phase 1/2 trial treating patients with molecularly identified, KRAS G12C-positive advanced solid tumors.